Using KM2760, the CCR4 mAb to treat MF/SS patients, Ito et al. showed a reduction in CCR4-expressing Treg number in CTCL mouse models, which again improved host immune response to the tumor cells (135). The gene discussed is CCR4; the disease is primary cutaneous T-cell non-Hodgkin lymphoma.